Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types

Mutationally corrupted cancer (stem) cells are the driving force of tumor development and progression. Yet, these transformed cells cannot do it alone. Assemblages of ostensibly normal tissue and bone marrow-derived (stromal) cells are recruited to constitute tumorigenic microenvironments. Most of the hallmarks of cancer are enabled and sustained to varying degrees through contributions from repertoires of stromal cell types and distinctive subcell types. Their contributory functions to hallmark capabilities are increasingly well understood, as are the reciprocal communications with neoplastic cancer cells that mediate their recruitment, activation, programming, and persistence. This enhanced understanding presents interesting new targets for anticancer therapy.

[1]  T. Salo,et al.  Gelatinase A (MMP-2), Collagenase-2 (MMP-8), and Laminin-5 γ2-Chain Expression in Murine Inflammatory Bowel Disease (Ulcerative Colitis) , 2004, Digestive Diseases and Sciences.

[2]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[3]  G. Giannelli,et al.  Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. , 1997, Science.

[4]  A. Hoffmann,et al.  Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis. , 2010, Genes & development.

[5]  Yuan Yuan Wang,et al.  Microenvironment and Immunology Cancer-Associated Adipocytes Exhibit an Activated Phenotype and Contribute to Breast Cancer Invasion , 2011 .

[6]  M. O. oude Egbrink,et al.  The Role of Blood Platelets in Tumor Angiogenesis , 1985 .

[7]  Max S Wicha,et al.  Breast cancer stem cells, cytokine networks, and the tumor microenvironment. , 2011, The Journal of clinical investigation.

[8]  F. Balkwill.  Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.

[9]  Masahiro Inoue,et al.  An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. , 2004, The Journal of clinical investigation.

[10]  Kati Räsänen,et al.  Activation of fibroblasts in cancer stroma. , 2010, Experimental cell research.

[11]  C. Tatu,et al.  Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences , 2010, Journal of cellular and molecular medicine.

[12]  Sam W. Lee,et al.  Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells. , 2007, Cancer research.

[13]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[14]  L. Coussens,et al.  Tumor stroma and regulation of cancer development. , 2006, Annual review of pathology.

[15]  P. Carmeliet,et al.  HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. , 2011, Cancer cell.

[16]  R. Weinberg,et al.  A Perspective on Cancer Cell Metastasis , 2011, Science.

[17]  J. Raufman,et al.  Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholyltaurine-induced proliferation of a human colon cancer cell line. , 2007, Biochemical pharmacology.

[18]  A. Hezel,et al.  LKB1; linking cell structure and tumor suppression , 2008, Oncogene.

[19]  A. Tsirigos,et al.  Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism , 2012, Cell cycle.

[20]  L. Naldini,et al.  Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. , 2011, Cancer cell.

[21]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[22]  Christopher Chiu,et al.  Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis , 2006, Proceedings of the National Academy of Sciences.

[23]  Laura J. Esserman,et al.  Leukocyte composition of human breast cancer , 2011, Proceedings of the National Academy of Sciences.

[24]  Hong Peng,et al.  Interactions between cancer stem cells and their niche govern metastatic colonization , 2011, Nature.

[25]  G. Dontu,et al.  Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. , 2011, Cancer research.

[26]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[27]  J. Hamzah,et al.  Modulation of the "blood-tumor" barrier improves immunotherapy , 2008, Cell cycle.

[28]  Ross Tubo,et al.  Mesenchymal stem cells within tumour stroma promote breast cancer metastasis , 2007, Nature.

[29]  J. Pollard,et al.  A Paracrine Loop between Tumor Cells and Macrophages Is Required for Tumor Cell Migration in Mammary Tumors , 2004, Cancer Research.

[30]  F. Sotgia,et al.  Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. , 2012, Annual review of pathology.

[31]  M. Barbacid,et al.  Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. , 2011, Cancer cell.

[32]  Bethan Psaila,et al.  The metastatic niche: adapting the foreign soil , 2009, Nature Reviews Cancer.

[33]  M. Atkins,et al.  Exploiting Regulatory T-cell Populations for the Immunotherapy of Cancer , 2007, Journal of immunotherapy.

[34]  A. Kate Sasser,et al.  Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor Progression , 2009, PloS one.

[35]  Ricky T. Tong,et al.  Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Choyke,et al.  Imaging of angiogenesis: from microscope to clinic , 2003, Nature Medicine.

[37]  R. Johnson,et al.  Endothelial Cell HIF-1α and HIF-2α Differentially Regulate Metastatic Success , 2012, Cancer cell.

[38]  A. Harris,et al.  Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer , 2000, The Journal of pathology.

[39]  J. Segall,et al.  Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors. , 2007, Cancer research.

[40]  Mina J. Bissell,et al.  Tissue architecture and function: dynamic reciprocity via extra- and intra-cellular matrices , 2009, Cancer and Metastasis Reviews.

[41]  L. Lazzarato,et al.  Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells , 2011, The Journal of experimental medicine.

[42]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[43]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[44]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[45]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[46]  R. Jain,et al.  NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. , 2005, The Journal of clinical investigation.

[47]  O. MacDougald,et al.  Adipocyte differentiation from the inside out , 2006, Nature Reviews Molecular Cell Biology.

[48]  P. Valet,et al.  Cancer-associated adipocytes promotes breast tumor radioresistance. , 2011, Biochemical and biophysical research communications.

[49]  D. Hanahan,et al.  Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. , 2006, Genes & development.

[50]  J. Koutcher,et al.  Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment. , 2012, Experimental cell research.

[51]  P. Sperryn,et al.  Blood. , 1989, British journal of sports medicine.

[52]  B. Fingleton,et al.  Resident stromal cell‐derived MMP‐9 promotes the growth of colorectal metastases in the liver microenvironment , 2007, International journal of cancer.

[53]  I. Gromova,et al.  Identification of Extracellular and Intracellular Signaling Components of the Mammary Adipose Tissue and Its Interstitial Fluid in High Risk Breast Cancer Patients , 2005, Molecular & Cellular Proteomics.

[54]  L. Coussens,et al.  Lymphocytes in cancer development: polarization towards pro-tumor immunity. , 2010, Cytokine & growth factor reviews.

[55]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[56]  Alberto Mantovani,et al.  Neutrophils in the activation and regulation of innate and adaptive immunity , 2011, Nature Reviews Immunology.

[57]  Zainab N. Khan,et al.  Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. , 2012, Cancer cell.

[58]  Napoleone Ferrara,et al.  Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.

[59]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[60]  I. Kasman,et al.  PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. , 2009, Cancer cell.

[61]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.

[62]  M. Sporn,et al.  Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. , 2011, The Journal of clinical investigation.

[63]  Z. Werb,et al.  Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.

[64]  M. Andreeff,et al.  Direct Evidence of Mesenchymal Stem Cell Tropism for Tumor and Wounding Microenvironments Using In Vivo Bioluminescent Imaging , 2009, Stem cells.

[65]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[66]  C. Heldin,et al.  Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. , 2001, Cancer research.

[67]  D. Hanahan,et al.  Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. , 1996, The Journal of clinical investigation.

[68]  Jeffrey W Pollard,et al.  Gene Expression Analysis of Macrophages That Facilitate Tumor Invasion Supports a Role for Wnt-Signaling in Mediating Their Activity in Primary Mammary Tumors , 2009, The Journal of Immunology.

[69]  Bonnie F. Sloane,et al.  Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.

[70]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[71]  Holger Gerhardt,et al.  Pericytes limit tumor cell metastasis. , 2006, The Journal of clinical investigation.

[72]  H. Dvorak,et al.  Tumor microenvironment and progression , 2011, Journal of surgical oncology.

[73]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[74]  M J Bissell,et al.  How does the extracellular matrix direct gene expression? , 1982, Journal of theoretical biology.

[75]  P. De Baetselier,et al.  Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. , 2010, Cancer research.

[76]  R. Rosenfeld.  Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[77]  L. Ellis,et al.  Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. , 1999, Cancer research.

[78]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[79]  J. Folkman,et al.  The combination of antiagniogenic agents to inhibit primary tumor growth and metastasis , 1993 .

[80]  F. Sotgia,et al.  Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth , 2011, Cell cycle.

[81]  P. Carmeliet,et al.  Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. , 2011, Current opinion in genetics & development.

[82]  Andrew H. Beck,et al.  Systematic Analysis of Breast Cancer Morphology Uncovers Stromal Features Associated with Survival , 2011, Science Translational Medicine.

[83]  J. Folkman,et al.  Mast cells and tumor angiogenesis , 1976, International journal of cancer.

[84]  Kazunori Kataoka,et al.  Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling , 2007, Proceedings of the National Academy of Sciences.

[85]  J. Massagué,et al.  Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. , 2011, Cancer cell.

[86]  C. Betsholtz,et al.  Endothelial/Pericyte Interactions , 2005, Circulation research.

[87]  M. Andreeff,et al.  Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells , 2008, Gene Therapy.

[88]  Dai Fukumura,et al.  Malignant cells facilitate lung metastasis by bringing their own soil , 2010, Proceedings of the National Academy of Sciences.

[89]  R. Kalluri,et al.  The role of stromal myofibroblast and extracellular matrix in tumor angiogenesis. , 2011, Genes & cancer.

[90]  Rakesh K Jain,et al.  Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. , 2002, The American journal of pathology.

[91]  M. Hendrix,et al.  Maspin: a tumor suppressing serpin. , 1996, Current topics in microbiology and immunology.

[92]  Richard O Hynes,et al.  Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. , 2011, Cancer cell.

[93]  L. Allen.  Stem cells. , 2003, The New England journal of medicine.

[94]  Z. Werb,et al.  Extracellular matrix degradation and remodeling in development and disease. , 2011, Cold Spring Harbor perspectives in biology.

[95]  J. Baselga,et al.  The Evolving War on Cancer , 2011, Cell.

[96]  M. Loeffler,et al.  Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. , 2006, The Journal of clinical investigation.

[97]  Peter Olson,et al.  Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. , 2010, Cancer cell.

[98]  D. Hanahan,et al.  Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[99]  A. Chadli.  THE CANCER CELL , 1924, La Presse medicale.

[100]  M. Giacca,et al.  Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.

[101]  V. Hu.  The Cell Cycle , 1994, GWUMC Department of Biochemistry Annual Spring Symposia.

[102]  J. Partanen,et al.  3D view to tumor suppression: lkb1, polarity and the arrest of oncogenic c-myc , 2009, Cell cycle.

[103]  G. Fuh,et al.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.

[104]  W. Hellstrom,et al.  J Urol , 2014 .

[105]  S. Vandenberg,et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.

[106]  John R Yates,et al.  Maspin and tumor metastasis , 2006, IUBMB life.

[107]  Gefeng Zhu,et al.  B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma , 2006, The Journal of experimental medicine.

[108]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[109]  Dr. Andreas von Deimling.  Neoplasia , 1997, Laboratory investigation; a journal of technical methods and pathology.

[110]  Craig Murdoch,et al.  Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. , 2008, Neoplasia.

[111]  N. Greenberg,et al.  Maspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells. , 2003, The Journal of urology.

[112]  Jing Xu,et al.  Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1 , 2009, The Journal of experimental medicine.

[113]  David A. Cheresh,et al.  Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin , 2007, Nature.

[114]  J. Massagué,et al.  VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. , 2011, Cancer cell.

[115]  L. Coussens,et al.  Inflammation, proteases and cancer. , 2006, European journal of cancer.

[116]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[117]  D. Hanahan,et al.  Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting , 2008, PLoS medicine.

[118]  H. Saya,et al.  Activated macrophages promote Wnt signalling through tumour necrosis factor-α in gastric tumour cells , 2008, The EMBO journal.

[119]  Lei Xu,et al.  Normalization of the vasculature for treatment of cancer and other diseases. , 2011, Physiological reviews.

[120]  J. Pollard,et al.  Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages , 2007, Molecular oncology.

[121]  B. Spiegelman,et al.  Molecular mechanisms of cancer development in obesity , 2011, Nature Reviews Cancer.

[122]  G. Mills,et al.  Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth , 2011, Nature Medicine.

[123]  H. Dvorak.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[124]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.

[125]  E. Brogi,et al.  Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. , 2011, Genes & development.

[126]  O. Casanovas.  The adaptive stroma joining the antiangiogenic resistance front. , 2011, The Journal of clinical investigation.

[127]  S. Krane,et al.  Stromal regulation of vessel stability by MMP14 and TGFβ , 2010, Disease Models & Mechanisms.

[128]  R. Noelle,et al.  Mast cells as regulators of adaptive immunity to tumours , 2009, Clinical and experimental immunology.

[129]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[130]  L. Coussens,et al.  Immune Cells and Inflammatory Mediators as Regulators of Tumor Angiogenesis , 2008 .

[131]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[132]  L. Coussens,et al.  Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. , 2010, Cancer research.

[133]  Melody A. Swartz,et al.  Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21 , 2010, Science.

[134]  O. Franco,et al.  Cancer associated fibroblasts in cancer pathogenesis. , 2010, Seminars in cell & developmental biology.

[135]  R. Weissleder.  Molecular Imaging in Cancer , 2006, Science.

[136]  M. Wendland,et al.  MRI of Tumor-Associated Macrophages with Clinically Applicable Iron Oxide Nanoparticles , 2011, Clinical Cancer Research.

[137]  Daniel T. Fisher,et al.  IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. , 2011, The Journal of clinical investigation.

[138]  Tomoyuki Shirai,et al.  MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. , 2005, Cancer cell.

[139]  A. Bardelli,et al.  Targeted therapies: how personal should we go? , 2012, Nature Reviews Clinical Oncology.

[140]  O. Vasiljeva,et al.  Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. , 2006, Cancer research.

[141]  William C Hines,et al.  Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression , 2011, Nature Medicine.

[142]  S. Ostrand-Rosenberg,et al.  Immune surveillance: a balance between protumor and antitumor immunity. , 2008, Current opinion in genetics & development.

[143]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[144]  R. Kerbel,et al.  Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models , 2009, Molecular Cancer Therapeutics.

[145]  Shahin Rafii,et al.  Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors , 2010, Nature Reviews Cancer.

[146]  D. Hanahan,et al.  Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. , 1999, Genes & development.

[147]  S. Rafii,et al.  Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.

[148]  Na Zhang,et al.  Deletion of Vascular Endothelial Growth Factor in myeloid cells accelerates tumorigenesis , 2008, Nature.

[149]  D. Bentrem,et al.  The significant role of mast cells in cancer , 2011, Cancer and Metastasis Reviews.

[150]  G. Evan,et al.  Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors , 2007, Nature Medicine.

[151]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[152]  A. Sica,et al.  Macrophages in cancer and infectious diseases: the 'good' and the 'bad'. , 2011, Immunotherapy.

[153]  F. Sotgia,et al.  Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment , 2011, Breast Cancer Research.

[154]  Ove Andrén,et al.  High‐throughput live‐cell imaging reveals differential inhibition of tumor cell proliferation by human fibroblasts , 2011, International journal of cancer.

[155]  Brian Bierie,et al.  A delicate balance: TGF‐β and the tumor microenvironment , 2007, Journal of cellular biochemistry.

[156]  D. Hanahan,et al.  Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.

[157]  Robert S. Kerbel,et al.  Antiangiogenic therapy: impact on invasion, disease progression, and metastasis , 2011, Nature Reviews Clinical Oncology.

[158]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[159]  F. Sotgia,et al.  Power surge: supporting cells "fuel" cancer cell mitochondria. , 2012, Cell metabolism.

[160]  Robert A. Weinberg,et al.  Heterogeneity of stromal fibroblasts in tumor , 2007 .

[161]  Mikala Egeblad,et al.  Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling , 2009, Cell.

[162]  Kristian Pietras,et al.  Hallmarks of cancer: interactions with the tumor stroma. , 2010, Experimental cell research.

[163]  A. Mantovani,et al.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.

[164]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[165]  M. Merad,et al.  Studying the mononuclear phagocyte system in the molecular age , 2011, Nature Reviews Immunology.

[166]  A. Lusis,et al.  Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. , 2010, Blood.

[167]  Michele De Palma,et al.  The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities , 2012, Molecular oncology.